HomeCompareCVALF vs MO

CVALF vs MO: Dividend Comparison 2026

CVALF yields 8.37% · MO yields 6.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MO wins by $45.3K in total portfolio value· pulled ahead in Year 7
10 years
CVALF
CVALF
● Live price
8.37%
Share price
$1.27
Annual div
$0.11
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.8K
Annual income
$1,420.80
Full CVALF calculator →
MO
Altria Group Inc.
● Live price
6.36%
Share price
$65.99
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.1K
Annual income
$30,159.17
Full MO calculator →

Portfolio growth — CVALF vs MO

📍 MO pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCVALFMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CVALF + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CVALF pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CVALF
Annual income on $10K today (after 15% tax)
$711.52/yr
After 10yr DRIP, annual income (after tax)
$1,207.68/yr
MO
Annual income on $10K today (after 15% tax)
$540.99/yr
After 10yr DRIP, annual income (after tax)
$25,635.29/yr
At 15% tax rate, MO beats the other by $24,427.61/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CVALF + MO for your $10,000?

CVALF: 50%MO: 50%
100% MO50/50100% CVALF
Portfolio after 10yr
$57.5K
Annual income
$15,789.98/yr
Blended yield
27.48%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

CVALF
No analyst data
Altman Z
5.0
Piotroski
4/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-7.2% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CVALF buys
0
MO buys
0
No recent congressional trades found for CVALF or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCVALFMO
Forward yield8.37%6.36%
Annual dividend / share$0.11$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$34.8K$80.1K
Annual income after 10y$1,420.80$30,159.17
Total dividends collected$11.3K$74.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: CVALF vs MO ($10,000, DRIP)

YearCVALF PortfolioCVALF Income/yrMO PortfolioMO Income/yrGap
1$11,537$837.09$10,570$780.30+$967.00CVALF
2$13,247$902.57$11,381$1,032.90+$1.9KCVALF
3$15,143$968.57$12,535$1,392.73+$2.6KCVALF
4$17,238$1,034.75$14,193$1,920.91+$3.0KCVALF
5$19,545$1,100.83$16,618$2,723.68+$2.9KCVALF
6$22,080$1,166.53$20,263$3,993.80+$1.8KCVALF
7← crossover$24,857$1,231.60$25,936$6,098.36$1.1KMO
8$27,893$1,295.80$35,166$9,775.01$7.3KMO
9$31,205$1,358.93$51,026$16,597.78$19.8KMO
10$34,810$1,420.80$80,113$30,159.17$45.3KMO

CVALF vs MO: Complete Analysis 2026

CVALFStock

Covalon Technologies Ltd. researches, develops, manufactures, commercializes, and licenses medical technologies and products in the United States, Canada, Europe, the Middle East, Asia, Latin America, and internationally. The company has 3 proprietary platform technologies, including collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; antimicrobial silicone adhesive platform that is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity; and medical coating platform, a proprietary process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. Its products include wound care dressings; surgical and peri-operative products; and infection management products. The company offers its products under the Covalon brand name through third-party distribution networks and company's direct sales force. It serves hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians' offices. The company is headquartered in Mississauga, Canada.

Full CVALF Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this CVALF vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CVALF vs SCHDCVALF vs JEPICVALF vs OCVALF vs KOCVALF vs MAINCVALF vs PMCVALF vs BTICVALF vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.